Weight regain after obesity treatment: mechanisms, predictors, and real-world evidence from the IGOBE program.

Weight regain is the defining challenge of obesity treatment and remains insufficiently addressed in current clinical paradigms. Despite substantial initial weight loss achieved through lifestyle, pharmacological, or surgical interventions, most individuals experience partial or complete regain over time, reflecting powerful and persistent biological adaptations that defend body weight. These include reductions in energy expenditure, sustained hormonal changes that promote appetite, and neurobehavioral mechanisms that favor increased energy intake, all of which are further modulated by genetic and epigenetic susceptibility. In this context, we integrate current mechanistic evidence with real-world data from the IGOBE program, a structured multidisciplinary lifestyle intervention, to provide novel insights into the dynamics of weight regain. While participants achieved comparable initial weight loss, long-term trajectories diverged markedly, revealing two distinct phenotypes: maintainers and regainers. Strikingly, baseline clinical and behavioral characteristics failed to predict outcomes. Individuals who ultimately regained weight displayed more favorable baseline lifestyle profiles, whereas sustained weight loss was associated with greater longitudinal behavioral change, particularly in physical activity, dietary patterns, and self-regulation. These findings challenge the prevailing assumption that weight regain is primarily a consequence of poor adherence and instead support a model in which long-term outcomes emerge from the interaction between biological pressures and the capacity for sustained behavioral adaptation. We argue that obesity management must be fundamentally reframed: long-term weight maintenance should replace initial weight loss as the primary therapeutic goal, and treatment should adopt a chronic care model integrating continuous support, personalized strategies, and, when appropriate, sustained pharmacotherapy.